TrialX at SCOPE 2026: Simplifying Patient Recruitment, Spotlighting Clinical Research Heroes — Coffee, Conversations & Key Insights

Team TrialX at SCOPE 2026: Sharib Khan (Co-founder & CEO), Wes Martz (Senior Director of Client Services), Beth Dickson (VP, Business Development), and Brandon Ramos (Sales Development Representative) SCOPE 2026 once again brought together leaders across…

SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders and More…

The 17th Annual SCOPE Summit once again brought together leaders across clinical operations, digital health, patient engagement, and data innovation to shape the future of clinical research. This year, the tone was clear: the industry is…

TrialX is Powering Global Studies with Multilingual Engagement, AI-Driven Trial Discovery & Remote Data Collection – on Earth and in Space

🦃 This holiday season, we’re especially grateful for partnerships that bring hope to patients and families. We are honored to power the AI-based clinical trial finder for ALK Positive, a patient-driven organization dedicated to improving the…

Leadership Spotlight: A Conversation with Lisa La Luna – Reflections on Diversity, Art, and the Future of Clinical Research

Throwback to October 13th! We were honored to power the Clinical Trial Finder for the groundbreaking Reflections initiative, a program transforming how communities engage with clinical research. Designed to enhance diversity in clinical trials and raise…

TrialX Updates: AI Innovations in Clinical Trials, Enhancing Diversity with AI Powered Clinical Trial Finder and more…

What’s New at TrialX! 🚀 Congratulations to the Reflections Collective Team! They won the Fierce DEI Awards in the Community Engagement and Outreach category, announced at the Patients as Partners Europe conference in London this month. True to its name,…

How TrialX’s Multilingual Capabilities Are Driving Global Clinical Trials

For decades, clinical trials have struggled with a deep-rooted problem: a lack of diversity. Racial and ethnic minorities, individuals in non-English-speaking communities, and patients outside of research-heavy geographies remain consistently underrepresented in studies. This isn’t just…